Share your opinion about this

Like
Comment
Favorite

Share your opinion about this news…

BREAKINGVIEWS-Novo Nordisk obesity feast no longer a free lunch

(The author is a Reuters Breakingviews columnist. The opinions expressed are her own.) By Aimee Donnellan LONDON, July 18 (Reuters Breakingviews) - The $603 bln drug group’s shares have more t

BREAKINGVIEWS-Novo Nordisk obesity feast no longer a free lunch

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":328874739536088,"tweetId":"328874739536088","gmtCreate":1721316901969,"gmtModify":1721316905428,"author":{"id":3583414482292207,"authorId":3583414482292207,"authorIdStr":"3583414482292207","name":"Woodbranch","avatar":"https://static.tigerbbs.com/60d7c475430bda5d8c7733c97fb4b6ac","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.02.01","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>Share your opinion about this news…</p></body></html>","htmlText":"<html><head></head><body><p>Share your opinion about this news…</p></body></html>","text":"Share your opinion about this news…","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/328874739536088","repostId":2452177348,"repostType":2,"repost":{"id":"2452177348","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1721293372,"share":"https://www.laohu8.com/m/news/2452177348?lang=&edition=full","pubTime":"2024-07-18 17:02","market":"us","language":"en","title":"BREAKINGVIEWS-Novo Nordisk obesity feast no longer a free lunch","url":"https://stock-news.laohu8.com/highlight/detail?id=2452177348","media":"Reuters","summary":"(The author is a Reuters Breakingviews columnist.  The opinions expressed are her own.)   By Aimee Donnellan      LONDON, July 18 (Reuters Breakingviews) - The $603 bln drug group’s shares have more t","content":"<html><body><p>(The author is a Reuters Breakingviews columnist.  The opinions expressed are her own.)</p><p>   By Aimee Donnellan</p><p>      LONDON, July 18 (Reuters Breakingviews) - The $603 bln drug group’s shares have more than trebled since 2021 on the back of booming sales of weight-loss treatment Wegovy. To justify that, it will need to keep coming up with new, even better products, and fend off rivals like Pfizer. Neither looks certain.</p><p>   Full view will be published shortly.</p><p>   Follow @aimeedonnellan on X</p><p>   CONTEXT NEWS</p><p>   Roche said on July 17 that a second drug candidate from its purchase of Carmot <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> yielded positive results in an early-stage trial, as the Swiss drugmaker asserted itself as a late contender in the race to develop obesity drugs. Novo Nordisk’s shares fell nearly 4% on the news.</p><p>   Pfizer said on July 11 that it plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year.</p><p>   The new drug is part of the second generation of weight-loss pills under development by companies including Eli Lilly and Novo Nordisk that will offer patients a more convenient alternative to injections.</p><p> (Editing by Neil Unmack and Oliver Taslic)</p><p>((For previous columns by the author, Reuters customers can click on    Aimee.Donnellan@thomsonreuters.com))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BREAKINGVIEWS-Novo Nordisk obesity feast no longer a free lunch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBREAKINGVIEWS-Novo Nordisk obesity feast no longer a free lunch\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-07-18 17:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>(The author is a Reuters Breakingviews columnist.  The opinions expressed are her own.)</p><p>   By Aimee Donnellan</p><p>      LONDON, July 18 (Reuters Breakingviews) - The $603 bln drug group’s shares have more than trebled since 2021 on the back of booming sales of weight-loss treatment Wegovy. To justify that, it will need to keep coming up with new, even better products, and fend off rivals like Pfizer. Neither looks certain.</p><p>   Full view will be published shortly.</p><p>   Follow @aimeedonnellan on X</p><p>   CONTEXT NEWS</p><p>   Roche said on July 17 that a second drug candidate from its purchase of Carmot <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> yielded positive results in an early-stage trial, as the Swiss drugmaker asserted itself as a late contender in the race to develop obesity drugs. Novo Nordisk’s shares fell nearly 4% on the news.</p><p>   Pfizer said on July 11 that it plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year.</p><p>   The new drug is part of the second generation of weight-loss pills under development by companies including Eli Lilly and Novo Nordisk that will offer patients a more convenient alternative to injections.</p><p> (Editing by Neil Unmack and Oliver Taslic)</p><p>((For previous columns by the author, Reuters customers can click on    Aimee.Donnellan@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","SG9999001176.USD":"United Global Healthcare Acc USD","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0238689110.USD":"贝莱德环球动力股票基金","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4581":"高盛持仓","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0058720904.USD":"联博国际健康护理基金A","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","NVO":"诺和诺德","BK4532":"文艺复兴科技持仓","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","BK4592":"伊斯兰概念","PFE":"辉瑞","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4534":"瑞士信贷持仓","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC"},"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2452177348","content_text":"(The author is a Reuters Breakingviews columnist.  The opinions expressed are her own.)   By Aimee Donnellan      LONDON, July 18 (Reuters Breakingviews) - The $603 bln drug group’s shares have more than trebled since 2021 on the back of booming sales of weight-loss treatment Wegovy. To justify that, it will need to keep coming up with new, even better products, and fend off rivals like Pfizer. Neither looks certain.   Full view will be published shortly.   Follow @aimeedonnellan on X   CONTEXT NEWS   Roche said on July 17 that a second drug candidate from its purchase of Carmot Therapeutics yielded positive results in an early-stage trial, as the Swiss drugmaker asserted itself as a late contender in the race to develop obesity drugs. Novo Nordisk’s shares fell nearly 4% on the news.   Pfizer said on July 11 that it plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year.   The new drug is part of the second generation of weight-loss pills under development by companies including Eli Lilly and Novo Nordisk that will offer patients a more convenient alternative to injections. (Editing by Neil Unmack and Oliver Taslic)((For previous columns by the author, Reuters customers can click on    Aimee.Donnellan@thomsonreuters.com))","news_type":1},"isVote":1,"tweetType":1,"viewCount":69,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":30,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}